Favipiravir (T-705)

Alias: T705; Avigan; T-705; T 705; 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide
Cat No.:V1430 Purity: ≥98%
Favipiravir (formerly T-705; T705; T 705; Avigan),an approved antiviral drug used to treat influenza in Japan, is a selective RNA-dependent RNA polymerase inhibitor.
Favipiravir (T-705) Chemical Structure CAS No.: 259793-96-9
Product category: DNA(RNA) Synthesis
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
10mg
25mg
50mg
100mg
250mg
500mg
1g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Favipiravir (formerly T-705; T705; T 705; Avigan), an approved antiviral drug used to treat influenza in Japan, is a selective RNA-dependent RNA polymerase inhibitor. It is being researched for the treatment of other viral infections, including SARS-CoV-2, and has been used to treat influenza virus infections in Japan.

Biological Activity I Assay Protocols (From Reference)
Targets
RdRP ( IC50 = 341 nM )
ln Vitro

Favipiravir (T 705) is an antiviral medication that specifically inhibits the influenza virus's RNA-dependent RNA polymerase. The RNA-dependent RNA polymerase (RdRP) of influenza and numerous other RNA viruses is specifically and potently inhibited by the novel antiviral drug favipiravir (T 705). Human DNA polymerase α, β, or γ with an IC50 greater than 1 mM is not inhibited by favipiravir-RTP. Given that the human RNA polymerase II IC50 is 905 μM, Favipiravir exhibits 2,650 times greater selectivity for the influenza virus RdRP, which is in line with its inability to inhibit host-cell DNA and RNA synthesis[1]. Favipiravir (T 705) functions as a prodrug; cell-line dependence is anticipated in its cytotoxicity. In cell culture, favipiravir inhibits MNV-induced CPE (EC50: 250±11 μM) and MNV RNA synthesis (EC50: 124±42 μM) in a dose-dependent manner. Favipiravir (T 705) exhibits relatively modest antiviral activity, but at a concentration of 100 μg/mL, it completely inhibits norovirus replication, causing little to no harm to the host cell (cell viability >80%)[2].

ln Vivo
Favipiravir (T 705) (30 mg/kg/day, orally) improves survival compare to placebo. At a dose of 33 mg/kg/day or more, favipiravir (T 705) offers considerable protection against the A/Duck/MN/1525/81(H5N1) virus, irrespective of the number of daily doses. Every mouse survives when fed four times a day[1].
Cell Assay
Using the MTS-based CPE reduction assay in the MNV/RAW 264.7 cell line, the antiviral activity of Favipiravir (T 705) is assessed. Thus, 96-well plates containing 1×104 cells/well of RAW 264.7 cells are seeded, and MNV is injected at a multiplicity of infection (MOI) of 0.01, either with or without a dilution series of Favipiravir (T 705) (3.13-200 μg/mL). Once the infected cells have shown full CPE after three days of incubation, cell culture supernatants are obtained and used for quantitative real-time RT-PCR (qRT-PCR) to measure the viral RNA load. A stock solution consisting of 2 mg/mL MTS and 46 g/mL PMS in PBS at pH 6-6.5 is diluted 1/20 in MEM for the MTS reduction assay. The optical density (OD) is measured at 498 nm two hours after 75 μL of MTS/PMS solution is added to each well. In order to determine the percentage of CPE reduction, one must calculate [(ODtreated)MNW−ODVC]/[ODCC-ODVC]×100. In this calculation, ODCC denotes the OD of the untreated, uninfected cells, while ODVC and (ODtreated)CC stand for the treated, virus-infected cells and untreated, infected cells, respectively. The concentration of a compound that, in 50% of cases, prevented virus-induced CPE is known as the EC50. Favipiravir concentrations are applied to uninfected cells for three days in order to assess the molecule's detrimental effects on the host cell using the MTS-method. The percentage of viable cells is computed as (ODtreated/ODCC)×100, where ODtreated refers to untreated uninfected cells treated with compound, and ODCC is the OD of untreated uninfected cells. The concentration of a compound at which 50% fewer viable cells are present is known as the CC50. CC50/EC50 is the formula used to compute the selectivity index (SI)[2].
Animal Protocol
Mice: It has also been demonstrated that favipiravir (T 705) shields mice from fatal influenza virus infections caused by a range of strains. When mice infected with lethal doses of influenza viruses A/Victoria/3/75(H3N2), A/Osaka/5/70(H3N2), or A/Duck/MN/1525/81(H5N1) are given favipiravir orally twice or four times a day for five days.
References

[1]. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54.

[2]. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C5H4FN3O2
Molecular Weight
157.1
Exact Mass
157.03
Elemental Analysis
C, 38.23; H, 2.57; F, 12.09; N, 26.75; O, 20.37
CAS #
259793-96-9
Appearance
White to off-white solid powder
SMILES
C1=C(N=C(C(=O)N1)C(=O)N)F
InChi Key
ZCGNOVWYSGBHAU-UHFFFAOYSA-N
InChi Code
InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
Chemical Name
5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
Synonyms
T705; Avigan; T-705; T 705; 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 31~100 mg/mL (197.3~636.5 mM)
Water: ~5 mg/mL (~31.8 mM)
Ethanol: ~22 mg/mL (~140.0 mM)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 6.3654 mL 31.8269 mL 63.6537 mL
5 mM 1.2731 mL 6.3654 mL 12.7307 mL
10 mM 0.6365 mL 3.1827 mL 6.3654 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05155527 Recruiting Drug: Ivermectin Tablets
Other: Placebo
COVID-19 Mahidol University February 10, 2022 Phase 2
NCT06024421 Not yet recruiting Drug: favipiravir
Drug: Placebo
Infectious Disease
Pharmacology
Institut National de la Santé
Et de la Recherche Médicale,
France
November 2023 Phase 1
NCT05940545 Recruiting Drug: Favipiravir
Drug: Ribavirin
CCHF Liverpool School of Tropical
Medicine
July 12, 2023 Phase 1
Phase 2
NCT04376814 Completed Drug: Favipiravir
Drug: Hydroxychloroquine
COVID-19
Favipiravir
Baqiyatallah Medical Sciences
University
March 29, 2020 Not Applicable
NCT04464408 Completed Drug: Favipiravir
Drug: Placebo
COVID-19 King Abdullah International
Medical Research Center
July 23, 2020 Phase 2
Phase 3
Biological Data
  • Favipiravir (T-705)

    Effect of oral administration of T-705 on prevention of death in influenza virus-infected mice. Antimicrob Agents Chemother. 2002 Apr;46(4):977-81.
  • Favipiravir (T-705)

    Effect of oral administration of T-705 on lung virus yield in influenza virus-infected mice. Antimicrob Agents Chemother. 2002 Apr;46(4):977-81.
Contact Us